Viral dose, radioiodide uptake, and delayed efflux in adenovirus-mediated NIS radiovirotherapy correlates with treatment efficacy

M. A. Trujillo, M. J. Oneal, S. J. McDonough, J. C. Morris

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We have constructed a prostate tumor-specific conditionally replicating adenovirus (CRAd), named Ad5PB-RSV-NIS, which expresses the human sodium iodine symporter (NIS) gene. LNCaP tumors were established in nude mice and infected with this CRAd to study tumor viral spread, NIS expression, and efficacy. Using quantitative PCR, we found a linear correlation between the viral dose and viral genome copy numbers recovered after tumor infection. Confocal microscopy showed a linear correlation between adenovirus density and NIS expression. Radioiodide uptake vs virus dose-response curves revealed that the dose response curve was not linear and displayed a lower threshold of detection at 10 7 vp (virus particles) and an upper plateau of uptake at 10 11 vp. The outcome of radiovirotherapy was highly dependent upon viral dose. At 10 10 vp, no significant differences were observed between virotherapy alone or radiovirotherapy. However, when radioiodide therapy was combined with virotherapy at a dose of 10 11 vp, significant improvement in survival was observed, indicating a relationship between viral dose-response uptake and the efficacy of radiovirotherapy. The reasons behind the differences in radioiodide therapy efficacy can be ascribed to more efficient viral tumor spread and a decrease in the rate of radioisotope efflux. Our results have important implications regarding the desirable and undesirable characteristics of vectors for clinical translation of virus-mediated NIS transfer therapy.

Original languageEnglish (US)
Pages (from-to)567-574
Number of pages8
JournalGene Therapy
Volume20
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Adenoviridae
Virion
Neoplasms
Viruses
Symporters
Viral Genome
Nude Mice
Confocal Microscopy
Radioisotopes
Iodine
Prostate
Therapeutics
Sodium
Polymerase Chain Reaction
Survival
Infection
Genes

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Viral dose, radioiodide uptake, and delayed efflux in adenovirus-mediated NIS radiovirotherapy correlates with treatment efficacy. / Trujillo, M. A.; Oneal, M. J.; McDonough, S. J.; Morris, J. C.

In: Gene Therapy, Vol. 20, No. 5, 05.2013, p. 567-574.

Research output: Contribution to journalArticle

Trujillo, M. A. ; Oneal, M. J. ; McDonough, S. J. ; Morris, J. C. / Viral dose, radioiodide uptake, and delayed efflux in adenovirus-mediated NIS radiovirotherapy correlates with treatment efficacy. In: Gene Therapy. 2013 ; Vol. 20, No. 5. pp. 567-574.
@article{3a05ac5dc92a4ae49407e0625967b35b,
title = "Viral dose, radioiodide uptake, and delayed efflux in adenovirus-mediated NIS radiovirotherapy correlates with treatment efficacy",
abstract = "We have constructed a prostate tumor-specific conditionally replicating adenovirus (CRAd), named Ad5PB-RSV-NIS, which expresses the human sodium iodine symporter (NIS) gene. LNCaP tumors were established in nude mice and infected with this CRAd to study tumor viral spread, NIS expression, and efficacy. Using quantitative PCR, we found a linear correlation between the viral dose and viral genome copy numbers recovered after tumor infection. Confocal microscopy showed a linear correlation between adenovirus density and NIS expression. Radioiodide uptake vs virus dose-response curves revealed that the dose response curve was not linear and displayed a lower threshold of detection at 10 7 vp (virus particles) and an upper plateau of uptake at 10 11 vp. The outcome of radiovirotherapy was highly dependent upon viral dose. At 10 10 vp, no significant differences were observed between virotherapy alone or radiovirotherapy. However, when radioiodide therapy was combined with virotherapy at a dose of 10 11 vp, significant improvement in survival was observed, indicating a relationship between viral dose-response uptake and the efficacy of radiovirotherapy. The reasons behind the differences in radioiodide therapy efficacy can be ascribed to more efficient viral tumor spread and a decrease in the rate of radioisotope efflux. Our results have important implications regarding the desirable and undesirable characteristics of vectors for clinical translation of virus-mediated NIS transfer therapy.",
author = "Trujillo, {M. A.} and Oneal, {M. J.} and McDonough, {S. J.} and Morris, {J. C.}",
year = "2013",
month = "5",
doi = "10.1038/gt.2012.71",
language = "English (US)",
volume = "20",
pages = "567--574",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Viral dose, radioiodide uptake, and delayed efflux in adenovirus-mediated NIS radiovirotherapy correlates with treatment efficacy

AU - Trujillo, M. A.

AU - Oneal, M. J.

AU - McDonough, S. J.

AU - Morris, J. C.

PY - 2013/5

Y1 - 2013/5

N2 - We have constructed a prostate tumor-specific conditionally replicating adenovirus (CRAd), named Ad5PB-RSV-NIS, which expresses the human sodium iodine symporter (NIS) gene. LNCaP tumors were established in nude mice and infected with this CRAd to study tumor viral spread, NIS expression, and efficacy. Using quantitative PCR, we found a linear correlation between the viral dose and viral genome copy numbers recovered after tumor infection. Confocal microscopy showed a linear correlation between adenovirus density and NIS expression. Radioiodide uptake vs virus dose-response curves revealed that the dose response curve was not linear and displayed a lower threshold of detection at 10 7 vp (virus particles) and an upper plateau of uptake at 10 11 vp. The outcome of radiovirotherapy was highly dependent upon viral dose. At 10 10 vp, no significant differences were observed between virotherapy alone or radiovirotherapy. However, when radioiodide therapy was combined with virotherapy at a dose of 10 11 vp, significant improvement in survival was observed, indicating a relationship between viral dose-response uptake and the efficacy of radiovirotherapy. The reasons behind the differences in radioiodide therapy efficacy can be ascribed to more efficient viral tumor spread and a decrease in the rate of radioisotope efflux. Our results have important implications regarding the desirable and undesirable characteristics of vectors for clinical translation of virus-mediated NIS transfer therapy.

AB - We have constructed a prostate tumor-specific conditionally replicating adenovirus (CRAd), named Ad5PB-RSV-NIS, which expresses the human sodium iodine symporter (NIS) gene. LNCaP tumors were established in nude mice and infected with this CRAd to study tumor viral spread, NIS expression, and efficacy. Using quantitative PCR, we found a linear correlation between the viral dose and viral genome copy numbers recovered after tumor infection. Confocal microscopy showed a linear correlation between adenovirus density and NIS expression. Radioiodide uptake vs virus dose-response curves revealed that the dose response curve was not linear and displayed a lower threshold of detection at 10 7 vp (virus particles) and an upper plateau of uptake at 10 11 vp. The outcome of radiovirotherapy was highly dependent upon viral dose. At 10 10 vp, no significant differences were observed between virotherapy alone or radiovirotherapy. However, when radioiodide therapy was combined with virotherapy at a dose of 10 11 vp, significant improvement in survival was observed, indicating a relationship between viral dose-response uptake and the efficacy of radiovirotherapy. The reasons behind the differences in radioiodide therapy efficacy can be ascribed to more efficient viral tumor spread and a decrease in the rate of radioisotope efflux. Our results have important implications regarding the desirable and undesirable characteristics of vectors for clinical translation of virus-mediated NIS transfer therapy.

UR - http://www.scopus.com/inward/record.url?scp=84877783337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877783337&partnerID=8YFLogxK

U2 - 10.1038/gt.2012.71

DO - 10.1038/gt.2012.71

M3 - Article

C2 - 22972493

AN - SCOPUS:84877783337

VL - 20

SP - 567

EP - 574

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 5

ER -